For a patient living with obesity, the drugs on the market today are largely injectable peptides, and the side effects and dosing burden are part of why better options matter. Zealand Pharma wants more candidates to choose from, and its newest obesity bet comes from a machine rather than a chemistry bench.
$30M upfront for machine-designed proteins
The Danish biotech has agreed to pay Generate Biomedicines $30M upfront for protein therapeutics aimed at obesity and other metabolic diseases. Two programs are covered at the start, and a third can be added later.
Research through candidate selection belongs to Generate, which is based in Somerville, Massachusetts. Once a candidate is picked, clinical development, regulatory filings and worldwide commercialization move to Zealand. Early preclinical milestones near $35M and tiered royalties sit on top of a total milestone package that could approach $1.2B.
Diversifying away from peptides
The logic is straightforward. Peptides are what Zealand sells and what its partners are developing, and recent readouts have left open how competitive those programs will be. Protein modalities widen the pipeline past peptides and small molecules.
Several groups apply generative modeling to protein design; Generate’s platform proposes sequences and structures, then tests them in the lab. In obesity, the goal is a biologic that could approach incretin peptide efficacy while avoiding some of their manufacturing and dosing limits.
The agreement lands amid a run of large AI-biology partnerships in 2026, where pharma pays a modest upfront for optionality and pushes the real money into milestones.
Zealand’s exposure is capped at $30M. What it collects depends on generated proteins surviving translation into human trials.
